The WSJ Health blog published this commentary noting that increasingly Big Pharma and Biosimilars (formerly generics only) are competing more head to head. Big Pharma is crossing more into biosimilar territory as they lose drugs to the patent cliff and try to claim some of the resulting biosimilar or generic revenue as their own. Generic/biosimilar competitors are increasing partnering with or buying companies that produce novel therapeutics as a means of expanding their offering and protecting themself from generic competition.
I'm not sure what the surprise is here. As the world competition becomes more global and the industry consolidates through mergers -- I think it is natural that these companies with start converging in a similar space. As I've posted here many times, I think a significant number of competitors will be selling innovative drugs, generics and biosimilars -- alone and in partnerships and there will soon be little distinction among the majority of the biggest players.
This seems to me to be merely the result of a natural evolution of a competitive market. Let the best men and women win. Soon you won't be able to tell the players without a score card.
Posted by Bruce Lehr July 26th 2011.